4

10x Genomics

10x Genomics is a biotechnology company that develops platforms for single-cell genomics, gene expression, and epigenomics.
10x Genomics
Leadership team

Serge Saxonov (Co-Founder and Chief Executive Officer)

Ben Hindson (Co-Founder and Chief Technology Officer)

Charles Dadswell  (Chief Financial Officer)

Number of Employees
0 - 50
Headquarters
Pleasanton, California, United States
Established
2012
Social Media
Summary

10x Genomics is a biotechnology company that develops platforms for single-cell genomics, gene expression, and epigenomics. The 10x Genomics platform enables researchers to study the behaviour of cells at single-cell resolution, providing insights into complex biological systems. 

The company's products include Chromium Systems, which enables the generation of high-resolution genetic data from single cells; Loupe Software, which facilitates the visualization and analysis of single-cell data; and Chromium Connect, which assists with the integration of data between different systems. 10x Genomics also provides various services such as single-cell sequencing and bioinformatics.


History

10x Genomics is a biotech company based in California that provides innovative solutions for genomic research. The company was founded in 2012 by Serge Saxonov and Ben Hindson, who had previously worked together at the biotech company Bio-Rad Laboratories.

The company's core technology is based on microfluidics and molecular barcoding, which allow researchers to study genetic information at a single-cell level. This technology has significant implications for understanding complex biological systems and developing new therapies for diseases such as cancer and autoimmune disorders.

Since its founding, 10x Genomics has rapidly grown and expanded its product offerings. In 2015, the company launched its first product, the Chromium Single Cell Controller, which enables high-throughput single-cell gene expression analysis. The company has since developed additional products, including the Visium Spatial Gene Expression Solution, which allows researchers to analyze gene expression in spatially defined tissue sections.

10x Genomics went public in 2019 and is listed on the Nasdaq stock exchange under the ticker symbol TXG. The company has received numerous awards and accolades for its technology and innovation, including being named to Forbes' list of America's Most Promising Companies in 2015.


Investment criteria

As a public company, 10x Genomics does not have stated investment criteria for external investors. However, investors who are interested in investing in 10x Genomics can evaluate the company based on its financial performance, growth potential, and competitive landscape.

  • Financial performance: Investors can review 10x Genomics' financial statements to assess the company's revenue growth, profitability, and cash flow. They can also look at key financial metrics such as gross margin and operating expenses to understand the company's financial health.
  • Growth potential: Investors can evaluate 10x Genomics' growth potential by assessing its product pipeline, research and development initiatives, and market opportunities. They can also consider the company's partnerships and collaborations, which may provide additional growth opportunities.
  • Competitive landscape: Investors should evaluate the competitive landscape in which 10x Genomics operates to understand the company's position within the industry. They can review competitors' products, market share, and financial performance to assess the potential risks and opportunities for 10x Genomics.

Values

10x Genomics is a biotechnology company that specializes in developing genomic and cellular analysis tools to accelerate research in life sciences and healthcare. While the company does not have a stated set of core values, its mission and goals are rooted in a commitment to innovation, collaboration, and social responsibility.

  • Innovation: 10x Genomics' primary focus is on developing cutting-edge technologies and tools to enable breakthroughs in scientific research and healthcare. The company is committed to pushing the boundaries of what is possible through innovation, creativity, and a willingness to take calculated risks.
  • Collaboration: 10x Genomics recognizes that the most significant scientific breakthroughs are often the result of collaboration and teamwork. The company values partnerships and collaborations with leading researchers, institutions, and organizations across the life sciences and healthcare industries. By working together, 10x Genomics and its partners aim to drive progress and achieve meaningful impact.
  • Social responsibility: 10x Genomics recognizes that its work has the potential to impact society in profound ways. The company is committed to using its technology and resources to address some of the most pressing challenges facing humanity, including disease, environmental degradation, and social inequality. 10x Genomics also prioritizes ethical considerations, including privacy and security, in all of its work.

Mission

At its core, 10x Genomics believes that the key to improving human health lies in better understanding the fundamental processes that underpin life. By developing tools that enable researchers to study the genome at unprecedented levels of resolution, the company aims to catalyze breakthrough discoveries in fields such as oncology, immunology, and neuroscience.

In pursuing its mission, 10x Genomics is committed to collaboration and partnership, working closely with leading researchers, institutions, and organizations across the life sciences and healthcare industries. The company is also dedicated to operating with a high degree of ethical and social responsibility, recognizing the potential impact of its work on society and the environment.


Portfolio

The company focused on developing innovative genomic and cellular analysis technologies, 10x Genomics' portfolio of products and services spans a broad range of applications and areas of research. Here are a few examples of the company's key offerings:

  • Single-cell genomics: 10x Genomics' Chromium technology enables researchers to study individual cells at unprecedented levels of resolution, capturing gene expression and other molecular information from tens of thousands of cells in a single experiment. This technology has enabled breakthrough discoveries in fields such as immunology, neurobiology, and cancer research.
  • Spatial genomics: 10x Genomics' Visium technology allows researchers to study gene expression and other molecular information within the context of tissue architecture, enabling new insights into the biology of diseases such as cancer.
  • Immune profiling: The company's Immune Profiling solution enables researchers to study the immune system at the level of individual cells, providing insights into the mechanisms of immune response and potential therapeutic targets for diseases such as autoimmune disorders and cancer.
  • Genome assembly: 10x Genomics' linked-read technology enables researchers to assemble complex genomes with high accuracy and completeness, providing a powerful tool for studying genetic variation and understanding the genetic basis of diseases.

References
10x Genomics
Leadership team

Serge Saxonov (Co-Founder and Chief Executive Officer)

Ben Hindson (Co-Founder and Chief Technology Officer)

Charles Dadswell  (Chief Financial Officer)

Number of Employees
0 - 50
Headquarters
Pleasanton, California, United States
Established
2012
Social Media